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ABSTRACT
After the advent of HAART, the clinical course of HIV infection has dramatically improved. Therefore, 
it seems appropriate to reevaluate the performance of bone marrow biopsy (BMB) as a diagnostic tool. 
The aim of the present study was to compare the reasons for performing a BMB and its diagnostic yield 
in HIV-patients before and after HAART. A total of 165 BMB specimens obtained from HIV-infected 
patients receiving care at the Hospital of Universidade Federal do Rio de Janeiro in two different periods 
(1986-1994 and 1999-2004) were analysed. The main reason for BMB examination in the fi rst period was 
fever (88%), which decreased in the second period (57%, p < 0.0001), when cytopenia (51%) was the 
leading reason for BMB, whereas in the fi rst period it accounted for only 30% (p = 0.008). A defi nitive 
diagnosis (infection, granulomas or lymphomas) was obtained in 28% of patients in the fi rst period and 
in 19% during the second period (p = 0.20). The diagnosis turned out as infections decreased from 16% 
in period 1 to 2% in period 2 (p = 0.003). Despite the the limitations in the evaluation of fever, the use of 
BMB must be considered on an individual basis, whenever less invasive alternatives have been exhausted, 
and should be complemented by a bone marrow aspiration for microbiological studies.
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INTRODUCTION
The role of bone marrow biopsy (BMB) as a 
diagnostic tool in human immunodefi ciency 
virus (HIV) infection remains controversial. In 
the early days of the epidemic, many published 
studies evaluated the role of BMB, especially to 
elucidate persistent fever, secondary infections, 
cytopenias, and to stage malignancy.1-7 After the 
advent of highly active antiretroviral therapy 
(HAART), the clinical course of HIV infection 
has dramatically improved.8 As the clinical spec-
trum of this disease has changed, it is appropri-
ate to reevaluate the performance of BMB as a 
diagnostic tool in the HAART scenario.9-11 The 
aim of the present study was to compare the di-
agnostic yield of BMB in HIV infected patients 
before and after HAART introduction. 
MATERIAL AND METHODS
All consecutive BMB specimens obtained from 
HIV-infected patients at the Hospital of Univer-
sidade Federal do Rio de Janeiro in two different 
periods were retrospectively analysed. Patients 
in group 1 had their BMB done from November 
1986 to April 1994, before the introduction of 
HAART in Brazil. Patients in group 2 had un-
dergone a BMB from January 1999 to May 2004, 
and were on HAART for at least three months. 
HIV infection was confi rmed in all patients ac-
cording to national guidelines. The institutional 
review board approved the study.
BMB samples were formalin fi xed, decalci-
fi ed and embedded in paraffi n. Sections were cut 
at 5 µm and the following stains were routinely 
applied: Hematoxylin-eosin (HE), Ziehl-Neelsen 
(ZN) for the presence of acid-fast bacilli, and pe-
riodic acid-Schiff (PAS) and Grocott’s methen-
amine silver (GMS) for the diagnosis of fungal 
infection. Each specimen was evaluated for over-
all cellularity, relative proportion of plasma cells, 
eosinophils, and for the presence of iron, dysplas-
tic changes, abnormal localization of immature 
precursors (ALIP), serous degeneration, lym-
phoid nodules, granulomas and neoplasia. Bone 
marrow cellularity was defi ned as normocellular 
(40-60%), hypocellular (< 40%) and hypercellu-
lar (> 60%). Plasmacytosis and eosinophilia were 
defi ned as the presence of 5% or more of plasma 
cells or eosinophils, respectively.
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Baseline demographic and clinical characteristics retrieved 
from the patient record were age at the time of BMB, sex, stage 
according to the WHO staging system,12 blood cell counts, 
clinical reason for BMB examination, and CD4 counts. CD4 
counts were not available before 1994. 
Categorical variables were compared with the chi-square 
test or Fischer’s exact test, as appropriate. A p-value of < 0.05 
was considered statistically signifi cant. The SPSS software, 
(Chicago, IL, US) was used to analyze the data. 
RESULTS 
A total of 165 BMB samples were available for analysis: 102 from 
group 1 and 63 from group 2. The median age was 36 (11-67) 
years, and was not statistically different among the two groups 
(35 and 38 years, respectively). The proportion of females in-
creased in group 2 (15% versus 32%, p = 0.01). The majority of 
the patients in both groups presented with stage 4 disease (77% 
in group 1 and 87% in group 2). BMB examination was mainly 
indicated in group 1 was the evaluation of fever (90/102, 88%), 
and this indication signifi cantly decreased in group 2 (35/63, 
57%, p < 0.0001). Conversely, the main reason for BMB in 
group 2 was the presence of cytopenias (32/63, 51%), signifi -
cantly more often than had been observed in group 1 (30/102, 
30%, p = 0.008). The third most common reason for BMB was 
the staging and/or investigation of lymphomas. In the fi rst pe-
riod, it accounted for 18% (18/102) of all indications, and 27% 
(17/63) in the second period (p = 0.17).
No differences in bone marrow histopathological 
features were observed between the two groups, ex-
cept for the more frequent finding of a hypercellular 
bone marrow in group 2 (18% versus 38%, p = 0.015). 
Overall, the main histopathological findings were the 
presence of serous degeneration (90%), ALIPs (21%), 
lymphoid nodules (12%), plasmacytosis (22%), eosi-
nophilia (30%), megakaryocytic dysplasia (85%), and 
iron deposits (58%).
The fi nal diagnosis of the bone marrow examination 
was classifi ed into four categories: infections, granulomas, 
lymphomas, and others (including myelodysplasia). A de-
fi nitive diagnosis either of infection, granulomas, or lym-
phomas was obtained in 29 (28%) patients in group 1 and 
in 12 (19%) patients in group 2 (p = 0.20). However, BMB 
disclosing an infectious diagnosis decreased from 16% 
(16/102) in group 1 to 2% (1/63) in group 2 (p = 0.003) 
(Table 1). Patients who had undergone a BMB for the 
evaluation of fever, a diagnosis of infection was obtained 
in 25/102 (25.5%) in group 1, but in only 5/63 (7.9%) pa-
tients in group 2 (p = 0.007).
CD4 cell counts were available for 55/63 patients (87%) 
in group 2. Lower CD4 counts (< 200 cells/µL) were observed 
in 39 patients (71%). No differences were found between 
patients with lower and higher CD4 counts, in group 2, re-
garding the diagnostic yield of the BMB (20% versus 12%, 
p = 0.7).
Table 1. Final diagnosis of bone marrow involvement according to the use of highly active antiretroviral 
therapy (HAART)
   Group 1 Group 2 
  n = 165 Pre-HAART HAART p-value
   n = 102 n = 63 
Main indications* 
Fever   125  90 (88%) 35 (57%) 0.0001
Cytopenia 62 30 (30%) 32 (51%) 0.008
Lymphoma 35 18 (18%) 17 (27%) 0.17
Infections  17 (11%) 16 (16%) 1 (2%) 0.003
 Tuberculosis 7 (4%) 6 (6%) 1 (2%) -
 Atypical mycobacteriosis  3 (2%) 3 (3%) - -
 Hystoplasmosis 6 (4%) 6 (6%) - -
 Cryptococcosis  1 (0.5%) 1 (1%) - -
Granuloma 16 (9%) 10 (10%) 6 (9%) 1.0
Lymphomas 8 (7%) 3 (3%) 5 (8%) -
 Hodgkin 4 (3%) 1 (1%) 3 (5%) 0.28
 Non-Hodgkin 4 (4%) 2 (2%) 2 (3%) -
Others 124 (75%) 73 (71%) 51 (81%) -
 Dysplasia 101 (61%) 59 (58%) 42 (67%) 0.32
 Hipoplasia 6 (4%) 6 (6%) - -
 Normal 17 (10%) 8 (8%) 9 (15%) 0.18
*More than one indication could be present.
Indication of bone marrow biopsy
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DISCUSSION
Bone marrow biopsy has been largely used as a diagnos-
tic tool in AIDS patients from the onset of the epidemic. 
Since the introduction of HAART, there have been sub-
stantial changes in epidemiological and clinical aspects 
of the epidemic. It is therefore appropriate to evaluate the 
impact of these changes on the indications and diagnostic 
yield of BMB in AIDS patients.
A comparison of the indications and results of BMB 
in patients treated before and after the introduction 
of HAART was performed. Some interesting findings 
emerged from this analysis: (1) The indication of BMB 
for evaluation of fever has decreased from 88% to 57%; 
and (2) a sharp decrease in the diagnosis of infections 
through BMB was observed, especially when BMB was 
performed for fever evaluation.
 These findings most likely reflect the reduction in the 
incidence of opportunistic infections brought about by 
HAART, and also by the introduction of effective prophy-
lactic measures. Moreover, the availability of less invasive 
medical procedures, such as imaging studies and specific 
laboratory tests, probably contributed to the lesser use of 
BMB in patients with fever. 
On the other hand, no difference was observed re-
garding the overall diagnostic yield of BMB in the two 
periods, a finding in line with previous observations.9 
Also, no differences regarding the histological features in 
samples of BMB between the two periods were found. 
Currently, the overall diagnostic yield of BMB in 
AIDS patients was 19%. Despite the somewhat limited 
yield in the evaluation of fever, the use of BMB must be 
considered on an individual basis whenever less invasive 
alternatives have been exhausted, and should be comple-
mented by a bone marrow aspiration for microbiological 
studies. 
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